Compare TG Therapeutics Inc (TGTX) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Wells Fargo & Co — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Wells Fargo & Co trades at $83.55 (market cap $248.06B). The key difference: Wells Fargo & Co is far larger — about 30.4× TG Therapeutics Inc's market cap, and Wells Fargo & Co pays a 2.44% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Wells Fargo & Co for 88 Days on average.
| TGTX | WFC | |
|---|---|---|
Market Cap | $8.16B | $248.06B |
Volume | 1,735,121 | 16,615,741 |
Sector | Health | Financials |
52-Week High | $59.06 | $96.40 |
52-Week Low | $26.94 | $73.42 |
Typical Hold Time | 16 Days | 88 Days |
Enterprise Value | $8.37B | $503.91B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Wells Fargo (WFC) trades at $82.06, up 2.24% on the day, with a bearish technical signal from moving averages. The stock's valuation appears attractive with a P/E of 11.92 and P/B of 1.5, while profitability remains strong with a 25.97% net income margin. Recent news includes a credit rating upgrade to 'A-' by S&P (Zacks Investment Research, 2026-10-01) and upcoming Q3 earnings on October 13, 2026 (Benzinga, 2026-09-29).
The outlook is mixed: analyst consensus targets $99.13 (46.66% buy ratings), but recent earnings misses and a negative cash flow trend in 2025 pose risks. Upside potential hinges on execution amid Fed policy changes and competitive pressures in the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
